Emerging insights underscore a need to look beyond seizures alone
Podcast content: This podcast is available to listen to online.
Listen to podcast online (https://www.buzzsprout.com/2243576/20120180)
Developmental and epileptic encephalopathies (DEEs) are among the most complex and challenging disorders in pediatric epilepsy. Advances in genetics, precision medicine and multidisciplinary care are reshaping how DEEs are understood and treated as new research reveals that improving outcomes requires looking beyond seizures alone.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“Years ago, we called this group of epilepsies epileptic encephalopathies, as they were characterized by frequent epileptic spikes on EEG and frequent seizures, which were together considered the direct cause of the neurological, cognitive and developmental symptoms that patients were having, regardless of etiology,” explains Cleveland Clinic pediatric epileptologist Elia Pestana Knight, MD. “Today, that concept has been redefined to acknowledge that the etiology also plays an important role in the development of epileptic discharges and seizures — and also in the neurocognitive and behavioral problems that these patients have.”
In the latest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Pestana Knight provides a broad update on current understanding and management of DEEs, exploring the following topics and more:
Click the podcast player above to listen to the 30-minute episode now or read on for an edited excerpt of its transcript. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.
Advertisement
This activity has been approved for AMA PRA Category 1 Credit™ and ANCC contact hours. After listening to the podcast, you can claim your credit here.
Podcast host Glen Stevens, DO, PhD: How frequently is surgery an option for patients with DEEs?
Elia Pestana Knight, MD: Surgery is an option for some of these patients, particularly those who have structural abnormalities. Therapies start with anti-seizure medications. When those are not enough or when there is a structural lesion, we can do epilepsy surgery — resective epileptic surgery, lesionectomy or hemispherectomy. When those are not possible, we can do corpus callosotomy for patients who are having seizures with significant falls and injuries, particularly in cases that have evolved to the well-known Lennox-Gastaut syndrome. Those patients typically will benefit from that.
And then there is also neuromodulation. You can do vagus nerve neurostimulation or deep brain stimulation or responsive neurostimulation wth the NeuroPace System. These are options that can be offered to these patients.
And for cases with genetic causes, the genetic diagnosis does not preclude the use of neurostimulation techniques. We shy away from epilepsy surgery in these patients because we know, for example, that patients who have a problem with channelopathies — in other words, the genetic mutation leads to channel malfunction — they don’t do as well with epilepsy surgery. These are groups in which we are very focused on precision medicine, such as repurposing drugs with other uses that can be tried for the management of epilepsy. Additionally, of course, we have gene therapy — we all have hope in the development of gene therapy for DEEs.
Advertisement
Dr. Stevens: Among patients who have gene-based abnormalities, are the epilepsies generalized or focal, or a little bit of both?
Dr. Elia Pestana Knight: Both. Patients can have generalized seizures. Or they can have predominantly focal seizures. But they can also have both. And patients may develop a different seizure type across the lifespan, so that they might start with generalized seizures and then develop some focal seizures or focal generalized seizures. Or they might start with a mix of epilepsy phenotypes from the get-go.
Advertisement
Advertisement
Phase 1 trial of azer-cel reports good preliminary safety and efficacy
Physical, occupational and speech therapists will provide state-of-the-art outpatient care
Milestone case report expands understanding of infectious risks for those on immunomodulatory therapies
Advanced technologies are changing expectations about what’s possible
A rare opportunity to design for speed, care coordination, recovery and continuous monitoring
Multidisciplinary, proactive approach also improved discharge outcomes
Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26
Inflammatory protein eotaxin-1 may be a marker of future cognitive decline